Novel breast probe reduces repeat surgeries

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 17 No 6
Volume 17
Issue 6

A novel intraoperative breast cancer probe developed in Israel is showing significant promise in the reduction of repeat procedures in patients undergoing breast-conserving surgeries, according to a study presented at the American Society of Breast Surgeons Annual Scientific Meeting.

A novel intraoperative breast cancer probe developed in Israel is showing significant promise in the reduction of repeat procedures in patients undergoing breast-conserving surgeries, according to a study presented at the American Society of Breast Surgeons Annual Scientific Meeting.

Using radiofrequency spectroscopy technology, the handheld MarginProbe (Dune Medical Devices, Caesarea, Israel) assesses margin malignancy status in real time during an initial lumpectomy and helps avoid repeat procedures by enabling doctors to intraoperatively identify positive margins and shave additional tissue.

The 300-patient randomized clinical trial was conducted at 11 Israeli medical centers. All patients were undergoing breast-conserving surgery. The study compared the ability of 35 surgeons to detect tumors at the resection margins with and without use of the device.

“In the device group, the surgeon applied the probe to the excised lumpectomy specimen, sampling 5 to 12 points per margin, and shaving additional tissue according to device readings,” said Tanir

Allweis, MD, of Hadassah Hebrew University Medical Center, Jerusalem, an investigator in the study who presented the results.

Number of repeat surgeries reduced


Use of the probe resulted in a 56% reduction in repeat lumpectomies (5.6% vs 12.7%, P = .0027). There was no significant difference between the two study arms in the volume of tissue removed or cosmetic outcome. In a subset of 173 patients with nonpalpable lesions, repeat surgery rates, including mastectomy, were 9.8% vs 20.9% (P = .02) for device and control arms, respectively, a 53% reduction.

The radiofrequency spectroscopy device includes a sterile, handheld probe and a portable console. As the tip of the probe is applied to excised lumpectomy tissue, radiofrequency signals are transmitted into the tissue.

After the signals are reflected back to the console, they are analyzed based on a specialized algorithm to determine the presence of malignant tissue in the measured area adjacent to the probe tip.

Recent Videos
Updated results from the 1b/2 ELEVATE study elucidate synergizing effects observed with elacestrant plus targeted therapies in ER+/HER2– breast cancer.
Patients with ESR1+, ER+/HER2– breast cancer resistant to chemotherapy may benefit from combination therapy with elacestrant.
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.